Home / Conditions / Renal Kidney
Renal Kidney: when insurers say no, reviewers often say yes
In 18 published external-review decisions involving renal kidney, independent physician reviewers overturned the insurer’s denial 55.6% of the time.
Published decisions
18
2001–2026
Overturned
55.6%
10 denials reversed
Most-fought treatments for renal kidney
What insurers denied — and how those fights ended.
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 10 | 80% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 7 | 28.6% |
Typical time to a decision
7 days
Most land between 4 and 20 days
Handled as urgent
61.1%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a positron emission tomography (PET) scan. The assessment of disease burden and therapeutic response in this patient with metastatic renal cell carcinoma is critical to her care and effective decision-making. The patient has extensive disease with soft tissue and bone lesions. She is not able to continue with contrast enhanced computed tomography (CT) imaging due to an iodine contrast allergy. CT imaging without contrast would not be useful for appropriate care of this patient. PET imaging has demonstrated effective detection of clear cell renal cancer metastases comparable or superior to contrast CT imaging.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for positron emission tomography (PET) (CPT 78815) with computed tomography (CT) for attenuation scans. Renal cell carcinoma most commonly metastasizes to the lungs, bone, liver, and brain. Metastatic bone lesions from renal cell carcinoma are typically lytic in nature. Bone scintigraphy has limited sensitivity in diagnosing lytic bony metastases in comparison to PET/CT, which has higher sensitivity and accuracy. In the peer-reviewed medical literature, it is noted that the utility of PET/CT is limited for renal cell carcinoma.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Nivolumab (Opdivo) injections (CPT code J9299) 292.5 mg intravenous (IV) every 14 days for six cycles. The patient is not eligible for U.S. Food and Drug Administration (FDA) standard approved use of Opdivo, as he has microsatellite stable disease (Smith and Desai). The FDA supports treatment with Opdivo for patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that “has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.” This patient has the standard care option of regorafenib for treatment of microsatellite stable disease. The recommendation for the combination of regorafenib with Opdivo is based on recent data from the phase 1b results of the REGONIVO trial.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for belzutifan (Welireg). Metastatic renal cell carcinoma mostly occurs sporadically and can be present as a component of von Hippel-Lindau disease (VHL). VHL is an inherited, autosomal-dominant syndrome manifested by a variety of benign and malignant tumors, including hemangioblastomas, retinal angiomas, endolymphatic sac tumors, renal cell carcinoma, pheochromocytomas, pancreatic cysts, and neuroendocrine tumors. Both surgical resection and radiation therapy have a role in the management of appropriately selected patients with sporadic tumors. According to National Comprehensive Cancer Network (NCCN) guidelines, the hypoxia inducible factor-2alpha (HIF-2alpha) inhibitor, Welireg, is an additional treatment option for patients with VHL-associated renal cell carcinoma.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for renal kidney was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.